CAPA E LOMBADA - Arca - Fiocruz

114
______. Requirements for the use of animal cells as in vitro substrates for
the production of biologicals. In: WHO Expert Committee on biological
standardization. Forty-seventh report (WHO Technical Report Series). Geneva:
WHO 1998; 878.
______. Guidelines for assuring the quality of pharmaceutical and biological
products prepared by recombinant DNA technology. Geneva: WHO 1991;
814.
______. Requirements for human interferons made by recombinant DNA
techniques. Geneva: WHO 1988; 771.
______. Acceptability of cell substrates for production of biologicals. Report
of a WHO Study Group. Geneva: WHO 1987a; 747.
______. Requirements for continuous cell lines used for biologicals
production. In: WHO Expert Committee on Biological Standardization. Thirtysixth
Report. Geneva: WHO 1987b; Annex 3, 745.
______. Requirements for Poliomyelitis Vaccine (Inactivated). In:
Requirements for Biological Substances. Manufacturing and Control Laboratories.
Report of a WHO Expert Group. Geneva: WHO 1966; 323.
______. Requirements for Poliomyelitis Vaccine (Inactivated). In:
Requirements for Biological Substances: 1. General Requirements for
Manufacturing Establishments and Control Laboratories; 2. Requirements for
Poliomyelitis Vaccine (Inactivated). Report of a Study Group. Geneva: WHO
1959; 178.
Wikimedia. Fluoxetine 3D. [online]. 2008 [capturado 01 out 2008]. Disponível em:
http://upload.wikimedia.org/wikipedia/commons/f/f5/S-fluoxetine-3D-vdW.png
Woodcock J. Follow-on protein products. [online]. Rockville, United States of
America; 2007 [capturado 15 jan 2009]. Disponível em:
http://www.fda.gov/ola/2007/protein32607.html
Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B et al. The
FDA´s assessment of follow-on protein products: a historical perspective.
Nat Rev Drug Discov 2007; 6: 437-442.
Woody RW. Circular dichroism of peptides and proteins. In: Nakanishi K,
Berova N, Woody RW (eds). Circular dichroism: principles and applications. New
York: VCH Publishers; 1994.